Intralesional and Perilesional Treatment of Skin Cancers

  • Christopher J. Arpey
  • Nicole M. Annest
  • Stephen B. Tucker
  • Ronald P. Rapini
  • Deborah F. MacFarlane


In the following chapter, various intralesional and perilesional agents that have been used in the treatment of skin cancers will be presented by practitioners familiar with their use. The four medications reviewed have been in widespread use for many years in the treatment of cutaneous neoplasms and extracutaneous neoplastic and inflammatory conditions. Therefore, the efficacy, toxicity, delivery, indications, and costs for these agents are well established, and they are widely available. However, the most common routes of administration for such medications are oral, intravenous, and topical. An intralesional and perilesional approach to therapy is less often utilized, leading to less familiarity in clinical practice. It is our hope that a detailed review of these agents delivered in such a manner, along with a variety of clinical examples, will facilitate their use in practice and increase the variety of treatment options available to patients with cutaneous tumors.


Squamous Cell Carcinoma Basal Cell Carcinoma Squamous Cell Cancer Verrucous Carcinoma Intralesional Injection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol. 1991;25:306–318.CrossRefPubMedGoogle Scholar
  2. 2.
    Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5:3394–3402.PubMedGoogle Scholar
  3. 3.
    Nystrom ML, Steele JP, Shamash J, et al. Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial. Melanoma Res. 2003;13:197–199.CrossRefPubMedGoogle Scholar
  4. 4.
    Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2644–2652.CrossRefPubMedGoogle Scholar
  5. 5.
    Sheen YS, Sheen MC, Sheu HM, et al. Squamous cell carcinoma of the big toe successfully treated by intra-arterial infusion with methotrexate. Dermatol Surg. 2003;29:982–983.CrossRefPubMedGoogle Scholar
  6. 6.
    Coker DD, Elias EG, Viravathana T, et al. Chemotherapy for metastatic basal cell carcinoma. Arch Dermatol. 1983;119:44–50.CrossRefPubMedGoogle Scholar
  7. 7.
    Bason MM, Grant-Kels JM, Govil M. Metastatic basal cell carcinoma: response to chemotherapy. J Am Acad Dermatol. 1990;22:905–908.CrossRefPubMedGoogle Scholar
  8. 8.
    Annest NM, Van Beek MJ, Arpey CJ, et al. Intralesional methotrexate injection for keratoacanthoma tumors: a retrospective study and review of the literature. J Am Acad Dermatol. 2007;56:989–993.CrossRefPubMedGoogle Scholar
  9. 9.
    Beham A, Regauer S, Soyer HP, et al. Keratoacanthoma: a clinically distinct variant of well differentiated squamous cell carcinoma. Adv Anat Pathol. 1998;5(5):269–280.CrossRefPubMedGoogle Scholar
  10. 10.
    Manstein CH, Frauenhoffer CJ, Besden JE. Keratoacanthoma: is it a real entity? Ann Plast Surg. 1998;40(5):469–472.CrossRefPubMedGoogle Scholar
  11. 11.
    Karaa A, Khachemoune A. Keratoacanthoma: a tumor in search of a classification. Int J Dermatol. 2007;46:671–678.CrossRefPubMedGoogle Scholar
  12. 12.
    Schwartz RA. Keratoacanthoma: a clinico-pathologic enigma. Dermatol Surg. 2004;30:326–333.CrossRefPubMedGoogle Scholar
  13. 13.
    LeBoit PE. Can we understand keratoacanthoma? Am J Dermatopathol. 2002;24:166–168.CrossRefPubMedGoogle Scholar
  14. 14.
    Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous cell carcinoma: three examples with metastases. Am J Dermatopathol. 1993;15:332–342.CrossRefPubMedGoogle Scholar
  15. 15.
    Sanders S, Busam KJ, Halpern AC, et al. Intralesional corticosteroid treatment of multiple eruptive keratoacanthomas: case report and review of a controversial therapy. Dermatol Surg. 2002;28:954–958.Google Scholar
  16. 16.
    Eubanks SW, Gentry RH, Patterson JW, et al. Treatment of multiple keratoacanthomas with intralesional fluorouracil. J Am Acad Dermatol. 1982;7:126–129.CrossRefPubMedGoogle Scholar
  17. 17.
    Leonard AL, Hanke CW. Treatment of giant keratoacanthoma with intralesional 5-fluorouracil. J Drugs Dermatol. 2006;5:454–456.PubMedGoogle Scholar
  18. 18.
    Morse LG, Kendrick C, Hooper D, et al. Treatment of squamous cell carcinoma with intralesional 5-Fluorouracil. Dermatol Surg. 2003;29:1150–1153.CrossRefPubMedGoogle Scholar
  19. 19.
    Sayama S, Tagami H. Treatment of keratoacanthoma with intralesional bleomycin. Br J Dermatol. 1983;109:449–452.CrossRefPubMedGoogle Scholar
  20. 20.
    de la Torre C, Losada A, Cruces MJ. Keratoacanthoma centrifugum marginatum: treatment with intralesional bleomycin. J Am Acad Dermatol. 1997;37:1010–1011.CrossRefPubMedGoogle Scholar
  21. 21.
    Andreassi A, Pianigiani E, Taddeucci P, et al. Guess what! Keratoacanthoma treated with intralesional bleomycin. Eur J Dermatol. 1999;9:403–405.PubMedGoogle Scholar
  22. 22.
    Klein E, Milgram H, Traenkle HL. Tumors of the skin. II: Keratoacanthoma; local effect of 5-fluorouracil (5-FU). Skin. 1962;1:153–156.PubMedGoogle Scholar
  23. 23.
    Bergin DJ, Lapins NA, Deffer TA. Intralesional 5-fluorouracil for keratoacanthoma of the eyelid. Ophthal Plast Reconstr Surg. 1986;2(4):201–204.CrossRefPubMedGoogle Scholar
  24. 24.
    Parker CM, Hanke CW. Large keratoacanthomas in difficult locations treated with intralesional 5-fluorouracil. J Am Acad Dermatol. 1986;14:770–777.CrossRefPubMedGoogle Scholar
  25. 25.
    Thiele JJ, Ziemer M, Fuchs S, et al. Combined 5-fluorouracil and Er:YAG laser treatment in a case of recurrent giant keratoacanthoma of the lower leg. Dermatol Surg. 2004;30:1556–1560.CrossRefPubMedGoogle Scholar
  26. 26.
    Feldman RJ, Maize JC. Multiple keratoacanthomas in a young woman: report of a case emphasizing medical management and a review of the spectrum of multiple keratoacanthomas. Int J Dermatol. 2007;46:77–79.Google Scholar
  27. 27.
    Mangas C, Bielsa I, Ribera M, et al. A case of multiple keratoacanthoma centrifugum marginatum. Dermatol Surg. 2004;30:803–806.CrossRefPubMedGoogle Scholar
  28. 28.
    Vergara A, Isaría MJ, Domínguez JD, et al. Multiple and relapsing keratoacanthomas developing at the edge of skin grafts site after surgery and after radiotherapy. Dermatol Surg. 2007;33:994–996.CrossRefPubMedGoogle Scholar
  29. 29.
    Street ML, White Jr JW, Gibson LE. Multiple keratoacanthomas treated with oral retinoids. J Am Acad Dermatol. 1990;23:862–866.CrossRefPubMedGoogle Scholar
  30. 30.
    Benoldi D, Alinovi A. Multiple persistent keratoacanthomas: treatment with oral etretinate. J Am Acad Dermatol. 1984;10:1035–1038.CrossRefPubMedGoogle Scholar
  31. 31.
    Benest L, Kaplan RP, Salit R, et al. Keratoacanthoma centrifugum marginatum of the lower extremity treated with Mohs micrographic surgery. J Am Acad Dermatol. 1994;31:501–502.CrossRefPubMedGoogle Scholar
  32. 32.
    Larson PO. Keratoacanthomas treated with Mohs micrographic surgery (chemosurgery): a review of forty-three cases. J Am Acad Dermatol. 1987;16:1040–1044.CrossRefPubMedGoogle Scholar
  33. 33.
    Goldschmidt H, Sherwin WK. Radiation therapy of giant aggressive keratoacanthomas. Arch Dermatol. 1993;129(9):1162–1165.CrossRefPubMedGoogle Scholar
  34. 34.
    Caccialanza M, Sopelana N. Radiation therapy of keratoacanthomas: results in 55 patients. Int J Radiat Oncol Biol Phys. 1989;16(2):475–477.CrossRefPubMedGoogle Scholar
  35. 35.
    Reymann F. Treatment of Keratoacanthomas with curettage. Dermatologica. 1997;155(2):90–96.CrossRefGoogle Scholar
  36. 36.
    Nedwich JA. Evaluation of curettage and electrodesiccation in treatment of keratoacanthoma. Australas J Dermatol. 1991;32(3):137–141.CrossRefPubMedGoogle Scholar
  37. 37.
    Sheridan AT, Dawber RP. Curettage, electrosurgery and skin cancer. Australas J Dermatol. 2000;41(1):19–30.CrossRefPubMedGoogle Scholar
  38. 38.
    Oh CK, Son HS, Lee JB, et al. Intralesional interferon alfa-2b treatment of keratoacanthomas. J Am Acad Dermatol. 2004;51(6):1040.Google Scholar
  39. 39.
    Dendorfer M, Oppel T, Wollenberg A, et al. Topical treatment with imiquimod may induce regression of facial keratoacanthoma. Eur J Dermatol. 2003;13 (1):80–82.PubMedGoogle Scholar
  40. 40.
    Goebeler M, Lurz C, Kolve-Goebeler ME, et al. Pancytopenia after treatment of keratoacanthoma by single lesional methotrexate infiltration. Arch Dermatol. 2001;137(8):1104–1105.PubMedGoogle Scholar
  41. 41.
    Cohen PR, Schulze KE, Nelson BR. Pancytopenia after a single intradermal infiltration of methotrexate. J Drugs Dermatol. 2005;4(5):648–651.PubMedGoogle Scholar
  42. 42.
    Melton JL, Nelson BR, Stough DB, et al. Treatment of keratoacanthomas with intralesional methotrexate. J Am Acad Dermatol. 1991;25:1017–1023.CrossRefPubMedGoogle Scholar
  43. 43.
    Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanomas. Clin Oncol. 2005;23:2346–2357.CrossRefGoogle Scholar
  44. 44.
    Greenway HT, Cornell RC, Tanner DJ, et al. Treatment of basal cell carcinomas with intralesional interferon. J Am Acad Dermatol. 1986;15:437–443.CrossRefPubMedGoogle Scholar
  45. 45.
    Mozzanica N, Cattaneo A, Boneschi L, et al. Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2 interferon. Arch Dermatol Res. 1990;282(5):311–317.CrossRefPubMedGoogle Scholar
  46. 46.
    Tong Y, Tucker SB. Normal human skin lymphocytic and Langerhans’ cell responses to intradermal interferon α2b injections. Am J Med Sci. 1993;306:23–27.CrossRefPubMedGoogle Scholar
  47. 47.
    Tucker SB, Polasek JW, Perri AJ, et al. Long term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. J Am Acad Dermatol. 2006;54:1033–1038.CrossRefPubMedGoogle Scholar
  48. 48.
    Tucker SB. Interferon-alpha treatment of basal cell and squamous cell skin tumors. Cancer Bull. 1993;45:270–274.Google Scholar
  49. 49.
    Edwards L, Berman B, Rapini RP, et al. Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy. Arch Dermatol. 1992;128:1486–1489.CrossRefPubMedGoogle Scholar
  50. 50.
    Carucci JA. Intralesional interferon alfa for treatment of recurrent lentigo maligna of the eyelid in a patient with primary acquired melanosis. Arch Dermatol. 2000;136:1415.CrossRefPubMedGoogle Scholar
  51. 51.
    Cornell RC, Greenway HT, Tucker SB, et al. Intralesional interferon therapy of basal cell carcinoma. J Am Acad Dermatol. 1990;23:694–700.CrossRefPubMedGoogle Scholar
  52. 52.
    Miller BH, Shavin JS, Cognetta A, et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluoruracil injectable gel. J Am Acad Dermatol. 1997;36:72–77.CrossRefPubMedGoogle Scholar
  53. 53.
    Odom RB, Goette DK. Treatment of keratoacanthomas with intralesional fluorouracil. Arch Dermatol. 1978;114:1779–1983.CrossRefPubMedGoogle Scholar
  54. 54.
    Goette DK, Odom RB. Successful treatment of keratoacanthoma with intralesional fluorouracil. J Am Acad Dermatol. 1980;2:212–216.CrossRefPubMedGoogle Scholar
  55. 55.
    Kurtis B, Rosen T. Treatment of cutaneous neoplasms by intralesional injections of 5-fluorouracil (5-FU). J Dermatol Surg Oncol. 1980;6:122–127.PubMedGoogle Scholar
  56. 56.
    Kraus S, Miller BH, Swinehart JM, et al. Intratumoral chemotherapy with fluorouracil/epinephrine injectable gel: a nonsurgical treatment of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1998;38:438–442.CrossRefPubMedGoogle Scholar
  57. 57.
    Avant WH, Huff RC. Intradermal 5-flurouracil in the treatment of basal cell carcinoma of the face. South Med J. 1976;69:561–563.PubMedGoogle Scholar
  58. 58.
    Hanke CW. Treatment of squamous cell carcinoma with intralesional 5-FU (Comment). Dermatol Surg. 2003;29(11):1153.Google Scholar
  59. 59.
    Kurtis B, Rosen T. Squamous cell carcinoma arising in a basal cell epithelioma treated with 5-fluorouracil. J Dermatol Surg Oncol. 1979;5:394–396.PubMedGoogle Scholar
  60. 60.
    Umezawa H, Maeda K, Takeuchi T, et al. New antibiotics, bleomycin A and B. J Antibiot. 1966;19:200–209.PubMedGoogle Scholar
  61. 61.
    Burger RM, Peisach J, Horwitz SB. Activated bleomycin: a transient complex of drug, iron and oxygen that degrades DNA. J Biol Chem. 1981;256:1636–1644.Google Scholar
  62. 62.
    Saitta P, Krishnamurthy K, Brown LH. Bleomycin in dermatology: a review of intralesional applications. Dermatol Surg. 2008;34:1299–1313.Google Scholar
  63. 63.
    Mizuno S, Ishida A. Selective enhancement of bleomycin cytotoxicity by local anesthetics. Biochem Biophys Res Commun. 1982;105:425–431.CrossRefPubMedGoogle Scholar
  64. 64.
    Belehradek M, Domenge C, Luboinski B, et al. Electrochemotherapy, a new antitumor treatment. Cancer. 1993;72:3694–3700.CrossRefPubMedGoogle Scholar
  65. 65.
    Glass F, Pepine M, Fenske N, et al. Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol. 1996;132:1353–1357.CrossRefPubMedGoogle Scholar
  66. 66.
    Torre C, Losada A, Cruces M. Keratoacanthoma centrifugum marginatum: treatment with intralesional bleomycin. J Am Acad Dermatol. 1997;37:1010–1011.CrossRefPubMedGoogle Scholar
  67. 67.
    Fantini F, Gualdi G, Cimitan A, et al. Metastatic basal cell carcinoma with squamous differentiation. Arch Dermatol. 2008;144(9):1186–1188.CrossRefPubMedGoogle Scholar
  68. 68.
    Omidvari S, Nezakatgoo N, Ahmadloo N, et al. Role of intralesional bleomycin in the treatment of complicated hemangiomas; prospective clinical study. Dermatol Surg. 2005;31:499–501.CrossRefPubMedGoogle Scholar
  69. 69.
    Bunney M. Intralesional bleomycin sulfate in treatment of recalcitrant warts. Clin Dermatol. 1985;3:189–194.CrossRefPubMedGoogle Scholar
  70. 70.
    Miller R. Nail dystrophy following intralesional injections of bleomycin for a periungual wart. Arch Dermatol. 1984;120:963–964.CrossRefPubMedGoogle Scholar
  71. 71.
    Polluck B, Sheehan-Dare R. Pulsed dye laser and intralesional bleomycin for treatment of resistant viral hand warts. Lasers Surg Med. 2002;30:135–140.CrossRefGoogle Scholar
  72. 72.
    Susser W, Whitaker-White D, Grant-Kies J. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40:367–398.CrossRefPubMedGoogle Scholar
  73. 73.
    Pienaar C, Graham R, Geldenhuys S, et al. Intralesional bleomycin for the treatment of hemangiomas. Plastic Reconstruct Surg. 2006;117:221–226.CrossRefGoogle Scholar
  74. 74.
    Smith EA, Harber FE, Leroy EG, et al. Raynaud’s phenomenon of a single digit following local intradermal bleomycin sulfate injection. Arthritis Rheum. 1985;28:459–461.CrossRefPubMedGoogle Scholar
  75. 75.
    Heller R, Jaroszeski M, Reintgen D, et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer. 1998;83:148–157.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Christopher J. Arpey
    • 1
  • Nicole M. Annest
    • 2
  • Stephen B. Tucker
    • 3
  • Ronald P. Rapini
    • 4
  • Deborah F. MacFarlane
    • 5
  1. 1.Department of DermatologyUniversity of Iowa Hospitals and ClinicsIowa CityUSA
  2. 2.Kaiser Permanente, Mohs Surgical Unit, Department of DermatologyLafayetteUSA
  3. 3.Department of DermatologyUniversity of Texas Health Science Center at HoustonHoustonUSA
  4. 4.Department of DermatologyUniversity of Texas Medical SchoolHoustonUS
  5. 5.Departments of Dermatology and Plastic SurgeryThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations